Leptin and Liver Enzymes Responses to Aerobic Training in Hepatitis c Patients

Overview

Exercise is one of the most vital components of health maintenance. Exercising regularly maintains the cardiovascular system health, promotes the health of liver, and declines the risks of complications induced by CHCV. Since overweight is the main risk factor for IR and type 2 DM which may speed the liver disease progression among HCV patients, exercise is very important for maintenance and loss of weight. Further, exercise can relieve the side effects of medications of HCV, improve immunity, promote a sense of well-being, reduce levels of chronic fatigue, improve blood oxygen levels and increase the endorphins excretion which makes the patients fully energized (Elgendi, Shebl A, Sliem M, and Gary FA, 2018).

Studies on exercise effect in patients with CHCV are quite scarce (de Sousa Fernandes et al., 2019). Decreased leptin levels by exercise positively modulate insulin signaling and inhibit pathology progression (Anaruma et al., 2019). Since studies investigated physical activity effect on regulating HCV related leptin levels are very little, the present study aimed to explore the response of serum leptin and liver enzymes to aerobic exercise in nondiabetic overweight men with CHCV.

Full Title of Study: “The Effect of Aerobic Exercise on Liver Enzymes in Overweight Prediabetic Patients With Hepatitis c”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: January 2021

Detailed Description

The study group (n=20) received three sessions of aerobic walking exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down. The control group (n=20) will receive no training.

Interventions

  • Behavioral: aerobic treadmill exercise
    • The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.

Arms, Groups and Cohorts

  • Experimental: study group
    • The study group (n=20) will receive three sessions of aerobic walking exercise per week for 3 months in addition to the traditional medical treatment
  • No Intervention: control group
    • The control group (n=20) will receive no training

Clinical Trial Outcome Measures

Primary Measures

  • Leptin
    • Time Frame: It will be after 12-week training
    • It will be measured in plasma
  • Liver enzymes
    • Time Frame: liver enzymes will be after 12-week training
    • Serum alanine and aspartate transaminases (AST), (ALT) will be measured in plasma

Secondary Measures

  • weight
    • Time Frame: It will be after 12-week training
    • With an empty bladder and stomach, weight will be measured for every participant
  • Waist circumference (WC)
    • Time Frame: It will be after 12-week training
    • WC will be measured with an inelastic tape at the umbilicus level
  • fasting blood glucose (FBG)
    • Time Frame: It will be after 12-week training
    • FBG will be measured by On Call ® Plus Acon, REF G113- 214, made in China

Participating in This Clinical Trial

Inclusion Criteria

  • Men with hepatitis C patients at least from 6 months
  • BMI ranged ≥ 25 to < 30 kg/m2.
  • fasting blood glucose level (FBG) < 100 mg/dl.
  • waist circumference < 102 cm.

Exclusion Criteria

  • Besides the excluded individuals who participated in any form of physical training in the last 6 months, excluded patients by a physician will be patients with acute or other hepatitis types, cirrhotic or hepatocellular carcinoma, renal or respiratory problems, cardiovascular and neurologic diseases, and hypertension

Gender Eligibility: Male

self-representation of gender identity

Minimum Age: 40 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cairo University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ali Mohamed Ali ismail, lecturer of Physical Therapy for Cardiovascular / Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University – Cairo University
  • Overall Official(s)
    • Ali Ismail, lecturer, Principal Investigator, Cairo University
  • Overall Contact(s)
    • Ali Ismail, lecturer, 02 01005154209, allooka2012@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.